Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSH | P09668 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716376 | 0.79 | KMT2A (0.35) | MEN1KMT2ACNR2CTSK | |
| SCHEMBL4716380 | 0.79 | MEN1 (0.41) | MEN1KMT2ACTSKMETAP2CTSL | |
| SCHEMBL16203420 | 0.79 | MEN1 (0.41) | MEN1KMT2ACTSKMETAP2CTSL | |
| SCHEMBL23970178 | 0.79 | MEN1 (0.41) | MEN1KMT2ACTSKMETAP2CTSL | |
| SCHEMBL13996915 | 0.78 | MEN1 (0.40) | MEN1KMT2ACTSKCTSLCTSB | |
| SCHEMBL25589751 | 0.78 | MEN1 (0.40) | MEN1KMT2ACTSKCTSLCTSB | |
| SCHEMBL25590340 | 0.77 | MEN1 (0.39) | MEN1KMT2ACNR2CTSKCTSL | |
| SCHEMBL24530159 | 0.77 | MEN1 (0.39) | MEN1KMT2ACNR2CTSKCTSL | |
| SCHEMBL23970350 | 0.75 | MEN1 (0.38) | MEN1KMT2ACNR2CTSKCTSL | |
| SCHEMBL6826567 | 0.75 | CTSK (0.36) | MEN1KMT2ACTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138348-B2 | Using coordination polymerization catalyst | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080182951-A1 | Chromium Pyridine Bis(Oxazoline) And Related Catalysts For Ethylene Dimerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080182989-A1 | Methods For Oligomerizing Olefins With Chromium Pyridine Mono-Oxazoline Catalysts | EXXONMOBIL CHEMICAL PATENTS INC. | 2008-07-31 | — | — | US | disclosed |
| WO-2008085657-A1 | CHROMIUM COMPLEXES OF PYRIDINE BIS (OXAZOLINE)- LIGANDS FOR ETHYLENE DIMERI ZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008085655-A1 | METHODS FOR OLIGOMERIZING OLEFINS WITH CHROMIUM PYRIDINE MONO-OXAZOLINE CATALYSTS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182989-A1 | Methods For Oligomerizing Olefins With Chromium Pyridine Mono-Oxazoline Catalysts | OXER1, OXGR1, OXA1L | GRN 1571/4885SORT1 3809/4885MEN1 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.